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PHYSICO-CHEMICAL-MANAGED KILLING 
OF PENICILLIN-RESISTANT STATIC AND 
GROWING GRAM-POSITIVE AND 
GRAM-NEGATIVE VEGETATIVE BACTERIA 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The invention described herein was made in part by an 
employee of the United States Government and may be 10 
manufactured and used by and for the Government of the 
United States for governmental purposes without the pay-
ment of any royalties thereon of therefor. 
FIELD OF INVENTION 	 15 
The present invention relates to the field of pharmaceutical 
compounds and more particularly to physico -chemical alter-
ation of macromolecular targets and target-accessibility to a 
drug or antitoxin resulting from inclusion of components of 20 
the Hofineister series. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates the non-substantial killing effect of a pH 25 
5.5 PBS solution having 1024 µg/ml cloxacillin at 22° C. on 
a logarithmic-phase methicillin-resistant Staphylococcus 
aureus (MRSA) culture over a 20 minute period. 
FIG. 2 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 512 µg/ml cloxacillin at 22° C. on a 30 
logarithmic-phase MRSA culture over a 20 minute period. 
FIG. 3 illustrates the non-substantial killing effect of a pH 
5.5 SS having 1024 µg/ml cloxacillin at 22° C. on a logarith-
mic-phase MRSA culture over a 20 minute period. 
FIG. 4 illustrates the killing effect of a pH 7.4 SS having 35 
512 µg/ml cloxacillin at 22° C. on a logarithmic-phase MRSA 
culture over a 60 minute period. 
FIG. 5 illustrates the killing effect of a pH 7.4 SS having 
512 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA 
culture over a 60 minute period. 40 
FIG. 6 illustrates the killing effect of a pH 7.4 SS having 
1024 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA 
culture over a 60 minute period. 
FIG. 7 illustrates the killing effect of a pH 7.4 SS having 
2048 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA 45 
culture over a 60 minute period. 
FIG. 8 illustrates the killing effect of a pH 7.4 SS having 
4096 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA 
over a 60 minute period. 
FIG. 9 illustrates the killing effect of a pH 7.4 SS having 50 
4096 µg/ml cloxacillin at 22° C. on a stationary-phase MRSA 
culture over a 24 hour period. 
FIG. 10 illustrates the killing effect of a pH 7.4 SS having 
512 µg/ml cloxacillin at 35'C. on a logarithmic-phase MRSA 
culture over a 20 minute period. 55 
FIG. 11 illustrates the killing effect of a pH 7.4 SS having 
1024 µg/ml cloxacillin at 35° C. on a logarithmic-phase 
MRSA culture over a 20 minute period. 
FIG. 12 illustrates the killing effect of a pH 7.4 SS having 
2048 µg/ml cloxacillin at 35° C. on a logarithmic-phase 60 
MRSA culture over a 20 minute period. 
FIG. 13 illustrates the killing effect of a pH 7.4 SS having 
4096 µg/ml cloxacillin at 35° C. on a logarithmic-phase 
MRSA culture over a 20 minute period. 
FIG. 14 illustrates the killing effect of a pH 7.4 SS having 65 
512 µg/ml cloxacillin at 35° C. on a stationary-phase MRSA 
culture over a 60 minute period.  
2 
FIG. 15 illustrates the killing effect of a pH 7.4 SS having 
1024 µg/ml cloxacillin at 35'C. on a stationary-phase MRSA 
culture over a 60 minute period. 
FIG. 16 illustrates the killing effect of a pH 7.4 SS having 
2048 µg/ml cloxacillin at 35'C. on a stationary-phase MRSA 
culture over a 60 minute period. 
FIG. 17 illustrates the killing effect of a pH 7.4 SS having 
4096 µg/ml cloxacillin at 35'C. on a stationary-phase MRSA 
culture over a 60 minute period. 
FIG. 18 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution at 22° C. and 35° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 60 minute period. 
FIG. 19 illustrates the non-substantial killing effect of a pH 
7.4 SS at 22° C. and 35' C. on a logarithmic-phasePseudomo-
nas aeruginosa culture over a 60 minute period. 
FIG. 20 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution at 22° C. and 35° C. on a stationary-phase 
Pseudomonas aeruginosa culture over a 60 minute period. 
FIG. 21 illustrates the non-substantial killing effect of a pH 
7.4 SS at 22° C. and 35° C. on a stationary-phase Pseudomo-
nas aeruginosa culture over a 60 minute period. 
FIG. 22 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 512 µg/ml cloxacillin at 22° C. on a 
logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
FIG. 23 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 1024 µg/ml cloxacillin at 22° C. on 
a logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
FIG. 24 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 2048 µg/ml cloxacillin at 22° C. on 
a logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
FIG. 25 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 4096 µg/ml cloxacillin at 22° C. on 
a logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
FIG. 26 illustrates the killing effect of a pH 7.4 SS having 
512 µg/ml cloxacillin at 22° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 27 illustrates the killing effect of a pH 7.4 SS having 
1024 µg/ml cloxacillin at 22° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 28 illustrates the killing effect of a pH 7.4 SS having 
2048 µg/ml cloxacillin at 22° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 10 minute period. 
FIG. 29 illustrates the killing effect of a pH 7.4 SS having 
4096 µg/ml cloxacillin at 22° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 10 minute period. 
FIG. 30 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 512 µg/ml cloxacillin at 35° C. on a 
logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
FIG. 31 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 1024 µg/ml cloxacillin at 35° C. on 
a logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
FIG. 32 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 2048 µg/ml cloxacillin at 35° C. on 
a logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
FIG. 33 illustrates the non-substantial killing effect of a pH 
7.4 PBS solution having 4096 µg/ml cloxacillin at 35° C. on 
a logarithmic-phase Pseudomonas aeruginosa culture over a 
20 minute period. 
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FIG. 34 illustrates the killing effect of a pH 7.4 SS having 
512 µg/ml cloxacillin at 35° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 35 illustrates the killing effect of a pH 7.4 SS having 
1024 µg/ml cloxacillin at 35° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 36 illustrates the killing effect of a pH 7.4 SS having 
2048 µg/ml cloxacillin at 35° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 37 illustrates the killing effect of a pH 7.4 SS having 
4096 µg/ml cloxacillin at 35° C. on a logarithmic-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 38 illustrates the killing effect of a pH 7.4 SS having 
512 µg/ml cloxacillin at 22° C. on a stationary-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 39 illustrates the killing effect of a pH 7.4 SS having 
1024 µg/ml cloxacillin at 22° C. on a stationary-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 40 illustrates the killing effect of a pH 7.4 SS having 
2048 µg/ml cloxacillin at 22° C. on a stationary-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
FIG. 41 illustrates the killing effect of a pH 7.4 SS having 
4096 µg/ml cloxacillin at 22° C. on a stationary-phase 
Pseudomonas aeruginosa culture over a 20 minute period. 
GLOSSARY 
As used herein, the term "humectant" refers to a substance 
that absorbs water, helps another substance retain moisture, 
and/or disrupts or affects the water activity of macromol-
ecules. Humectants include compounds in the Hofineister 
series, including, but not limited to chaotropes, kosmotropes, 
and astringents or styptics, such as alum, Burow's solution 
(i.e., aluminum acetate), and silver nitrate, which at concen-
trations of approximately 10 mM or less also acts as an 
anti-toxin and antiseptic. 
As used herein, the term "penicillin" refers to any of a 
group of broad-spectrum antibiotic drugs of the central for-
mula R C,H 1 ,N2O4S, obtained from penicillin molds or 
produced synthetically, and which are most active against 
Gram-positive bacteria principally due to a beta-lactam ring 
reacting with a -serine-X-X-lysine-amino acid motif in the 
bacteria's transpeptidases, where X is any amino acid. Peni-
cillins are used in the treatment of various bacterial infections 
and diseases. Penicillins include, but are not limited to, methi-
cillin, cloxacillin, amoxicillin, ampicillin, carbenicillin, 
dicloxacillin, oxacillin, and therapeutic equivalents. 
As used herein, the term "salt" refers to a chemical com-
pound derived from an acid by replacing a hydrogen, wholly 
or partly, with a metal or an electropositive radical. This 
includes ionic products of Bronsted-Lowry acid-base reac-
tions and ionic products of Lewis acids in water, i.e., conju-
gate bases, where both these forms of salts are found within 
the Hofineister series. 
As used herein, "SS" is an abbreviation for a salt solution 
for denaturing, i.e., altering the structure of, macromolecules, 
and which is comprised of compounds within the Hofineister 
series. 
As used herein, "PBS" is an abbreviation for non-denatur-
ing phosphate buffered saline, a buffer solution commonly 
used to suspend and wash cells. 
BACKGROUND 
Both Gram-positive and Gram-negative pathogenic bacte-
ria are causing significant health problems around the world 
due to these bacteria developing, or innately presenting, bio- 
4 
chemical mechanisms that thwart medical management by 
various types of antibiotics. Effective use of pencillins, one 
major class of antibiotics, is particularly being threatened. 
For examples, Gram-positive methicillin-resistant Staphylo- 
5 coccus aureus (MRSA) has become resistant to control by 
penicillin, and Pseudomonas aeruginosa, an opportunistic 
member of Gram-negative bacteria, is innately beyond con-
trol of penicillins. 
One area of concern is hospital-acquired or nosocomial 
to parenteral antibiotic-resistant bacterial infections from topi-
cal colonized bacteria or suppurating infections. These types 
of bacteria frequently escape sterilization efforts prior to inva-
sive procedures allowing them to enter the body and establish 
15 infection. 
The acquiring of penicillin resistance by bacteria is life-
threatening and is being addressed by the pharmaceutical 
industry through the development of new generations ofpeni-
cillins. The pharmaceutical industry largely directs its efforts 
20 to creating new molecular alterations of existing penicillins in 
order to circumvent continually evolving resistance that in 
turn defeats efficacy of such new penicillins. Each generation 
of penicillins successively targets penicillin-resistant mecha-
nisms in the bacterial coat in a way designed to circumvent 
25 biochemical resistance mechanisms that have evolved within 
pathogenic bacteria to resist previous generations of penicil-
lin. It is unlikely that this cycle of new biochemical speci-
ficity for penicillin activity, followed by evolving resistance 
to that specificity, will be therapeutically successful since the 
30 percentages of penicillin-resistant pathogenic variants that 
defeat antibiotic management is rapidly increasing. 
Penicillins bind to penicillin-binding proteins (PBPs) in 
the bacterial coat, and especially in Gram-positive bacteria 
35 those targets tend to evolve into non-binding or non-acces-
sible motifs where, for example, one binding motif is said to 
be a 4-amino acid sequence -serine-X-X-lysine- that provides 
covalent acylation of serine by the beta-lactam ring of peni-
cillins. In Gram-negative bacteria, resistance to penicillin is 
40 additionally complicated by the presence of transporters in 
the coat-associated outer membrane that export the influx of 
penicillin, and by similarly located porins that can restrict 
uptake of penicillin. Therefore, it is important to resolve both 
the evolved resistance to binding of penicillin to amino acid 
45 target motifs and the blockage of uptake of penicillin into 
cells, which together largely account for observed antibiotic 
resistance. 
It is known that covalent binding of penicillins to PBPs of 
actively replicating bacterial cells leads to defective coats, 
50 which ultimately cause cell lysis and death. It is known that 
this covalent binding is commonly defeated by evolution of 
structural alteration in PBPs during development of penicillin 
resistance. 
In addition, penicillin transport mechanisms also require 
55 proteins of specific structure to perform the function of peni-
cillin efflux. Structural alterations of these proteins by pH, 
salt concentration, or dehydration are often reversible. For 
example, for at least one strain of MRSA, penicillin resistance 
is observed at pH 7.4; however, penicillin sensitivity is 
6o returned when those bacteria are exposed to penicillin at pH 
5.6. Conversely to physico -chemically induced reversible 
denaturation, covalent binding of penicillin to PBP targets is 
not reversible, but rather immutable whether achieved in 
growing or static bacterial cells. 
65 	 It is desirable to have a system and method for killing 
topical bacteria known to be penicillin-resistant, particularly 
MRSA and Pseudomonas aeruginosa. 
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It is desirable to have a system and method for reversing the 
levels of penicillin-resistant bacterial infections that plague 
individuals in both community and hospital settings. 
It is desirable to have a system and method for managing 
penicillin-resistance by mechanisms other than biochemical 
advances in the structure and/or activity of penicillin. 
It is further desirable to have a system and method for 
altering in situ targets and inaccessibility of penicillin in 
bacteria by physico -chemical treatments, providing novel 
paradigms for effective topical applications of antibiotics and 
other drugs and antitoxins. 
SUMMARY OF THE INVENTION 
The present invention is embodied as a pharmaceutical 
solution at pH 7.4 comprised of high concentrations of phos-
phate, sulfate, and acetate anions, potassium and ammonium 
cations, a trace of free ammonia, penicillin, and water. In an 
exemplary embodiment, the SS is applied within a range of 
temperatures, specifically 22'C. and 35° C. The SS is capable 
of inducing alteration of bacterial in situ target proteins to 
create sensitivity of the bacteria to otherwise ineffective peni-
cillins. 
DETAILED DESCRIPTION OF INVENTION 
For the purpose of promoting an understanding of the 
present invention, references are made in the text to exem-
plary embodiments of a system and method for the physico-
chemical alteration of penicillin-binding proteins in penicil-
lin-resistant Gram-positive and Gram-negative bacteria to 
induce sensitivity to otherwise ineffective penicillin, only 
one of which is described herein. It should be understood that 
no limitations on the scope of the invention are intended by 
describing these exemplary embodiments. One of ordinary 
skill in the art will readily appreciate that alternate but func-
tionally equivalent use of compounds, solvents, concentra-
tions, pH, and methods may be used to expand biochemical 
target reactivity and accessibility to reactive drugs and anti-
toxins. The inclusion of additional elements, such as drugs 
and anti-toxins, depending upon the specific biochemical tar-
gets and conditions involved, may be deemed readily appar-
ent and obvious to one of ordinary skill in the art. Specific 
elements disclosed herein are not to be interpreted as limiting, 
but rather as a basis for the claims and as a representative basis 
for teaching one of ordinary skill in the art to employ the 
present invention. 
Moreover, the terms "substantially" or "approximately" as 
used herein may be applied to modify any quantitative repre-
sentation that could permissibly vary without resulting in a 
change in the basic function to which it is related. 
The physico -chemical aspect of the SS, less penicillin, is 
conceived upon knowledge of water activity relative to bio-
logical macromolecular rearrangements, and the knowledge 
that temperature and pH also affect these rearrangements. 
The specifics of the SS, less penicillin, are taken from the 
extensive Hofineister series for enhancing reversible denatur-
ation of macromolecules in Gram-positive bacteria (e.g., 
methicillin-resistant Staphylococcus aureus) and Gram-
negative bacteria (e.g., Pseudomonas aeruginosa). The 
Hofineister series is comprised of compounds known to effect 
water activity and stability of a substantial and varied range of 
macromolecules. The physico -chemical conditions ofrevers-
ible denaturation rearrange biological macromolecules, 
thereby altering target motifs in protein, inhibiting structure-
specific protein activities, altering passive diffusion through 
structural barriers, and imposing a temporal static state upon 
6 
many metabolic processes, thereby improving outcome from 
coincident therapeutic treatment of targets. That is, such a 
disrupted and static condition in bacteria can be used as an 
advantage by including one or more different drugs or anti- 
5 toxins in this denaturing solution; drugs and anti-toxins can 
include a range of known biochemical agents, such as peni-
cillin, antiseptics, or disinfectants selected for compatibility 
with normal tissue at the site of topical application. In this 
embodiment, cloxacillin, an otherwise substantially ineffec- 
io tive penicillin, was chosen and proved to be highly efficient in 
directly killing bacteria normally resistant to penicillin. 
FIGS. 1 through 41 illustrate the efficiency of a SS formu-
lation derived from members of the Hofineister series for 
physico -chemically inducing alteration of in situ target pro- 
15 teins to establish sensitivity of Gram-positive (i.e., MRSA) 
and Gram-negative bacteria (i.e., Pseudomonas aeruginosa) 
to otherwise ineffective penicillins. 
The SS formulation at pH 7.4, but not pH 5.5, is effective in 
reversing penicillin-resi stance in a methicillin-resistant strain 
20 of Staphylococcus aureus (MRSA) and in Pseudomonas 
aeruginosa, important bacterial pathogens. The SS affects 
water activity, which in turn alters the macromolecular struc-
ture of the target. In this manner, penicillin-resistant proteins 
are rearranged by physico -chemical conditions such that 
25 covalent binding of penicillins is allowed andthe structures of 
penicillin transport proteins are altered or thereby inactivated 
to defeat the function of penicillin efflux. 
In an exemplary embodiment for treatment of planktonic 
bacteria, the SS contains high, at times saturated, concentra- 
30 tions of phosphate, sulfate, and acetate anions, potassium and 
ammonium cations, plus a small concentration of free ammo-
nia, all prepared in water, and applied at 22° C. or 35° C. For 
example, in one embodiment, the molar concentrations of the 
phosphate, sulfate, and acetate anions may be 3.1 M, 0.4 M, 
35 and 0.2 M, respectively, and the potassium and ammonium 
cations may be 2.6 M and 3.7 M, respectively. In an exem-
plary embodiment, ammonium hydroxide is added to the SS 
in order to bring the SS to the desired pH (e.g., pH 7.4), 
resulting in a small amount of free ammonia. In various other 
40 embodiments, sulfuric acid, acetic acid, a combination 
thereof, or another acid is added to lower the pH of the SS. In 
various embodiments, each compound may have a molar 
concentration ranging from 0.01 M to 4.0 M. In addition, the 
SS may include any of the compounds in the Hofineister 
45 series; the specific formula of the SS may be adjusted for 
maximal physico -chemical effectiveness in each specific 
application. 
In various physico-chemical embodiments, the pH, con-
centrations, solvents and/or temperature of the formulations 
50 may vary in order to maximize the effectiveness of macro-
molecular rearrangements and the outcome for different 
pathological biomolecular targets, all with regard for the tol-
erance of the normal tissue involved in topical applications. 
For example, the temperature may range from freezing to 43' 
55 C., the limiting temperature for thermal pain sensation. In 
various embodiments, the solvent (i.e., water) may be 
blended with or replaced with a substance(s) that is known to 
affect water activity and macromolecular rearrangements, 
such as alcohols (e.g., ethanol, propanol, butanol) or aprotic 
60 solvents (e.g., dimethyl acetamide, dimethyl formamide, 
dimethyl sulfoxide). 
In an exemplary embodiment, the SS is prepared to an 
effectivepH of7.4. Invarious other embodiments, the SS may 
be prepared to a pH ranging from 3.5 to 10. The pH may be 
65 varied to maximize the effectiveness of the macromolecular 
rearrangements and the outcome for different pathological 
biomolecular targets. 
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In an exemplary embodiment, the SS formulation, often 
acting as a humectant, is dictated by the alteration of water 
activity that leads to reversible denaturation ofbiomolecules, 
both those that are targets and those affecting accessibility to 
targets, thereby maximizing the effectiveness of the macro-
molecular arrangements and the resulting outcome. In vari-
ous embodiments, the formulation of SS may be varied by the 
addition of additives that affect the water activity of biomol-
ecules. These additives are taken from the Hofineister series, 
and include chaotropes and kosmotropes, including humec-
tants characterized as astringents or styptics, such as alum, 
Burow's solution (i.e., aluminum acetate), and silver nitrate. 
These additives are used to effect the reversible denaturation 
ofbiomolecules resulting in effective presentation of a variety 
of new biomolecular targets to drugs or anti-toxins, such as 
silver nitrate, contained within the topical solutions. 
FIGS.1 through 17 illustrate kill curve time course experi-
ments of stationary and logarithmic-phase MRSA bacterial 
suspensions exposed to PBS as well as denaturing SS at pH 
5.5 or pH 7.4 in the presence of cloxacillin concentrations 
spanning from 512 µg/ml to 4096 µg/ml. Experiments were 
conducted at 22° C. or 35° C. The completion time for the 
experiments ranged from 20 minutes to 24 hours. 
For these experiments, the MRSA strain was grown over-
night in Mueller-Hinton broth (MH)+2% NaCl at 35° C., 
subcultured into fresh media, and grown to mid-logarithmic 
phase. The cells were centrifuged and resuspended in pH 7.4 
MH+2% NaCl to produce an OD... nm known to indicate 
logarithmic-phase or stationary-phase of growth. An appro-
priate volume of cells was added to 1 ml of buffered SS in a 10 
ml Falcon tube to yield a final concentration of ca. 1x10 $ 
colony forming units (CFU)/ml, except for the experiments of 
FIGS. 1-4 where the final concentration of ca. 1 x 10 6 CFU/ml 
applies. Survival was determined for bacteria held for varied 
exposure times of up to 24 hours in the SS or in PBS at pH 5.6 
or pH 7.4, each altered with cloxacillin concentrations rang-
ing in doublings from 512 µg/ml to 4096 µg/ml. Survival was 
measured from samples held at 22° C. and 35° C. After 
exposure, samples of 50 ld were then withdrawn and a serial 
dilution series established. Cells were then plated on MH+2% 
NaCl agar plates and incubated at 22° C. or 35° C. for CFU 
formation, after which colonies were counted, surviving frac-
tions recorded, and survival curves constructed. Triplicate 
experiments were conducted for each exposure condition. 
The cells were treated under static conditions in all cases and 
treatments were always made on cells held in salt solutions, 
never on cells held in growth media. In addition to logarith-
mic-phase cells, stationary-phase cells removed from growth 
cycle were also treated. 
Cells exposed to SS at pH 7.4 in the presence of cloxacillin 
are killed. Killing is more efficient for logarithmic-phase cells 
than for stationary-phase cells. Both logarithmic-phase and 
stationary-phase cells are killed more effectively by treatment 
at 35° C. than treatment at 22° C. 
Killing efficiency is evaluated as therapeutically sufficient 
according to the 10-5 level of killing in 5 minutes specified by 
the British Standard BS EN 1276:1997 Chemical Disinfec-
tants and Antiseptics, which is referred to as the gold standard 
for efficacy of bactericidal agents. Typically, agents meeting 
the British Standard are too toxic for human topical applica-
tion. However, this is not a restriction for effective SS con-
taining cloxacillin used in the illustrated embodiment. 
As developed in FIGS. 1 through 4, substantial killing of 
static logarithmic-phase MRSA by cloxacillin is achieved at 
pH 7.4 at 22° C. for SS only. PBS at pH 5.5 or at pH 7.4 is not 
effective, and neither is SS at pH 5.5. Regarding the results 
shown in FIG. 4, no survivors were seen on any of the treated 
8 
plates; therefore, the surviving fraction for all time points is 
less than the 2x10-4 indicated as a conservative maximum 
allowed for the dilution factor plated. Experiments were also 
conducted on MRSA logarithmic-phase cells with SS alone at 
5 22° C. No killing effect was seen at pH 5.6 or pH 7.4 for SS 
alone. 
As FIGS. 5 through 9 illustrate, the efficiency of killing of 
stationary-phase MRSA cells at 22° C. does not provide the 
10-5 level of killing in 5 minutes specified by the British 
10 Standard. However, at the highest concentration of cloxacil-
lin, that is, 4096 µg/ml, the 10 -5 level of killing is achieved in 
3 hours, as detailed in FIG. 9. 
As shown in FIGS. 10 through 13, killing is enhanced by 
15 exposure of logarithmic-phase MRSA to cloxacillin at 35° C. 
As FIGS. 14 through 17 illustrate, the enhanced killing 
extends to stationary cells exposed at 35° C. as well. The 
efficiency of killing of both logarithmic-phase and stationary-
phase MRSA cells at 35° C. approaches or exceeds the 10 -5 
20 level of killing in 5 minutes specified by the British Standard. 
The level of killing is concentration dependent and is based 
upon the conditions of the treatment, such as species and 
initial sensitivity/resistance, whether the cells are in a station-
ary or logarithmic growth phase, temperature, and specific 
25 Hofineister series compounds used. 
FIGS. 18 through 41 illustrate kill curve time-course 
experiments of stationary-phase and logarithmic-phase 
Pseudomonas aeruginosa bacterial suspensions exposed to 
PBS, to SS, to PBS in the presence of cloxacillin concentra- 
30 tions spanning from 512 µg/ml to 4096 µg/ml, or to SS in the 
presence of cloxacillin concentrations spanning from 512 
µg/ml to 4096 µg/ml. Experiments were conducted at 22° C. 
or 35° C. over the course of 10, 20, or 60 minutes. 
Pseudomonas aeruginosa cells were prepared as described 
35 above for MRSA with a few exceptions. The Pseudomonas 
aeruginosa cells were first grown in trypticase soy broth and 
then frozen in aliquots, which were later rescued into MH 
broth+2% NaCl for use as in the MRSA experiments. An 
appropriate volume of cells was added to 1 ml of comparative 
40 salt solutions in a 10 ml Falcon tube to yield a final concen-
tration of ca. 1 x 10 $ colony forming units (CFU)/ml. Survival 
was determined for bacteria held for varied exposure times of 
up to 60 minutes in PBS, in SS, in PBS altered with cloxacillin 
concentrations ranging in doublings from 512 µg/ml to 4096 
45 µg/ml, or in SS containing cloxacillin concentrations ranging 
in doublings from 512 µg/ml to 4096 µg/ml. The salt solutions 
were compared at a pH of 5.6 or 7.4. Survival was measured 
from samples held at 22° C. or 35o C. After exposure, samples 
of 50 µl were then withdrawn and a serial dilution series 
50 established. Cells were then plated on MH+2% NaCl agar 
plates and incubated at 22° C. or 35° C. for CFU formation, 
after which colonies were counted, surviving fractions 
recorded, and survival curves constructed. Triplicate experi-
ments were conducted for each exposure condition. The cells 
55 were treated under static conditions in all cases and treat-
ments were always made on cells held in salt solutions, never 
on cells held in growth media. In addition to logarithmic-
phase cells, stationary-phase cells removed from growth 
cycle were also treated. 
60 	 FIGS. 18 through 21 show the results of the control experi- 
ments. For the control experiments, logarithmic-phase 
Pseudomonas aeruginosa cells were treated in PBS (FIG. 18) 
or SS (FIG. 19), and stationary-phase Pseudomonas aerugi-
nosa were treated in PBS (FIG. 20) or SS (FIG. 21). All 
65 experiments were conducted at both 22° C. and 35o C. for 60 
minutes. No substantial killing was observed for any of these 
controls. 
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FIGS. 22 through 25 illustrate the non-substantial killing 	 tant bacteria at room temperature is notable in that the killing 
	
logarithmic-phase Pseudomonas aeruginosa using a PBS 	 effectiveness is established in both logarithmic-phase and 
	
solution with cloxacillin concentrations ranging from 512 	 stationary-phase Gram-positive and Gram-negative bacteria. 
	
µg/ml to 4096 µg/ml at pH 7.4. The experiments were con- 	 The embodiment of discovery and application described 
ducted at 22° C. for 20 minutes. 	 5 for physico -chemically induced alteration of in situ target 
	
FIGS. 26 through 29 illustrate the efficiency of killing 	 proteins producing creation of sensitivity to otherwise inef- 
	
logarithmic-phase Pseudomonas aeruginosa using SS with 
	
fective penicillin is of great value in regard to both concepts 
	
cloxacillin concentrations ranging from 512 µg/ml to 4096 	 and applications for continuing efforts to remedy clinical 
	
µg/ml at pH 7.4. For cloxacillin concentrations of 2048 µg/ml 	 penicillin-resistance, and by extension a spectrum of related 
and 4096 µg/ml, the experiments were conducted at 22° C. for io drug-resistance. 
	
20 minutes. For cloxacillin concentrations of 512 µg/ml and 
	
The fact that penicillin-resistant static bacteria, both Gram- 
	
1024 µg/ml, the experiments were conducted at 22° C. for 10 	 positive and Gram-negative, are killed directly using a topi- 
	
minutes. At all concentrations of cloxacillin, the SS, but not 	 cally innocuous solution immediately applies to topical treat- 
	
the PBS solution, was substantially efficient in killing 	 ments such as those involved in pre-surgical fields so that 
Pseudomonas aeruginosa. 	 15 contaminating penicillin-resistant bacteria will be purged 
	
FIGS. 30 through 33 illustrate the non-substantial killing of 	 prior to surgical procedures, thus eliminating subsequent 
	
logarithmic-phase Pseudomonas aeruginosa using a PBS 	 parenteral infections that currently plague clinical invasive 
	
solution with cloxacillin concentrations ranging from 512 	 procedures. Topical applications include, but are not limited 
	
µg/ml to 4096 µg/ml at pH 7.4. The experiments were con- 	 to skin colonization, suppurating infections, infections of the 
ducted at 35° C. for 20 minutes. 	 20 eye, nares, throat and mouth, wounds, burns, encysted infec- 
	
FIGS. 34 through 37 illustrate the substantial killing of 	 tions, cellulitis, fulminating fasciitis, and also bacterial infec- 
	
logarithmic-phase Pseudomonas aeruginosa using the SS 	 tion upon internal structures, such as the vagina, urinary tract 
	
with cloxacillin concentrations ranging from 512 µg/ml to 	 and bladder, peritoneal cavity, large intestine, lung and tra- 
	
4096 µg/ml at pH 7.4. The experiments were conducted at 35° 	 chea, stomach, etc., all of which are accessible to instillation 
C. for 20 minutes. 	 25 procedures. 
	
FIGS. 38 through 41 illustrate the substantial killing of 
	
In addition, bacterial infections are a complicating factor in 
	
stationary-phase Pseudomonas aeruginosa using SS with 	 space travel. Injuries and radiation burns do not heal as well in 
	
cloxacillin concentrations ranging from 512 µg/ml to 4096 	 space, resulting in nagging injuries which may affect an astro- 
	
µg/ml at pH 7.4. The experiments were conducted at 22° C. 	 naut's performance. The present invention provides a new 
for 20 minutes. 	 3o ability to fight infections in space. 
	
Killing is more efficient for cells exposed to higher con- 	 Bacterial infections are also a major factor for the Depart- 
	
centrations of cloxacillin. In the embodiments shown, the 	 ment of Defense, especially during war times. Often, injuries 
	
highest concentration of cloxacillin tested was 4096 µg/ml; 	 that occur in the field become infected with the subject bac- 
	
however, it is not necessarily the maximum effective or tol- 	 teria and are barely treatable. Use of the present invention 
erated concentration. The concentration of cloxacillin or 35 provides an improved method for wound and burn healing. 
	
other drug may be varied depending on the contact effect 	 Likewise, the Department of Homeland Security is concerned 
	
required for topical applications in any given situation. That 	 about infections that result from radiation burns occurring at 
	
is, the preferred concentration should be determined for each 
	
dirty bomb sites. The use of the present invention would 
specific application. 	 provide a new and simple way of dealing with that issue. 
	
The use of various concentrations of compounds from the 	 40 	 The present invention operates in physico -chemical mode, 
	
Hofineister series can affect macromolecular hydration and 	 which exposes normally inaccessible target motifs for cova- 
	
protein denaturation, which may expose novel penicillin- 	 lent binding of penicillin, thus demonstrating for the first time 
	
binding amino acid motifs of PBPs and other non-specific 	 a mechanism of action for penicillin that is outside the dogma 
	
proteins. In addition, high salt concentrations inactivate 	 of biochemical action of penicillin upon only transpepidases 
efflux transporters and porins. As a result, both penicillin- 45 in actively growing bacterial cells. 
	
resistant Gram-positive and Gram-negative pathogenic bac- 	 The present embodiment claims rearrangement of macro- 
	
teria maybe created as penicillin-sensitive by physico-chemi- 	 molecules using compounds from the Hofineister series, 
	
cal denaturation induced by exposure to the embodied SS and 	 thereby yielding new target motifs accessible by drugs and/or 
	
related salt solutions when containing penicillin. It is 	 anti-toxins carried in the SS, which may be applied topically 
expected that under these specific conditions, universal cre-  50 to manage resistant or problematic organisms and/or macro- 
	
ation of protein target sensitivity to penicillin results from 	 molecules. The scope of this discovery includes topical appli- 
	
such physico -chemical treatment, that is, a field effect of 	 cations for treatment of bacteria; viruses; molds and yeasts; 
	
covalentbinding of proteins to penicillin is established during 	 topical parasites, such as ring-worm, ticks, and cutaneous and 
	
the physico-chemical treatment by SS in the presence of 	 mucocutaneous Leishmania; and pathological macromol- 
penicillin. This field effect, whereby any affected bacterial 55 ecules, such as bacterial exotoxins and endotoxins, snake and 
	
proteins may be modified to enhance penicillin-binding, pro- 	 spider venoms, super-antigens, and prions. "Topical applica- 
	
motes direct killing and allows, for the first time, the potential 	 tion" includes application not only to skin, but also to cystic 
	
application of penicillin to control static cells, including sta- 	 and suppurating infections, wounds, burns, nares, throat, 
	
tionary-phase cells, as well as actively growing cultures of 	 mouth, as well as all instillations such as to the urinary tract 
bacteria. Penicillin dissolves well in the SS described and 6o and bladder, vagina, peritoneal cavity, large intestine, stom- 
	
may be used for treatment in the form of a topical application. 	 ach, lung, and trachea. The mechanism of denaturation and 
	
Cloxacillin at relatively high concentration in the SS sub- 	 rearrangement of macromolecules, and not only proteins, 
	
stantially kills static logarithmic-phase and static stationary- 	 contributes to the disruption of pathologic processes by com- 
	
phase penicillin-resistant MRSA and Pseudomonas aerugi- 	 pounds of the Hofineister series, opening new accessibility to 
nosa cells rapidly upon exposure at room temperature, and 65 molecular target motifs for effective management by drugs, 
	
the degree of killing is advanced using variables of pH and 	 such as penicillins, and anti-toxins, such as silver ions, carried 
	
temperature. This substantial killing of static penicillin-resis- 	 in specifically optimized SS. Combinations of drugs and anti- 
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toxins may be applied in this regard. For example, in topical 
applications of the SS to fulminating fasciitis, a condition 
requiring rapid and multiple reversals of currently resistant 
pathologic processes, penicillin may be included to kill bac-
teria and silver ions may be included to inactivate super-
antigens. 
The present embodiment claims management of water 
activity and structure associated with macromolecules inbac-
terial pathogens by use of compounds of the Hofineister 
series, and examines the substantial killing effects due to new 
target motifs that react with penicillin in planktonic bacteria 
during exposures to the SS. Topical clinical applications of 
the SS carrying drugs and/or anti-toxins will, however, 
encounter sessile, as well as planktonic bacteria, the principal 
additional barrier to accessibility by drugs and/or anti-toxins 
then being the biofilm of polysaccharides, mucopeptides, etc. 
secreted by and covering the sessile bacteria. It is expected 
that dehydration and denaturation by humectant-like and 
other compounds from the Hofineister series in the SS will 
permeabilize this highly hydrated biofilm to drugs and/or 
anti-toxins, as well as expose new target motifs and inactivate 
outer membrane-associated accessibility barriers as shown in 
the embodiment herein. 
What is claimed is: 
1. A pharmaceutical composition comprising: a potassium 
cation; an ammonium cation; a phosphate anion; a sulfate 
anion; an acetate anion; and a penicillin; wherein said potas-
sium cation, said ammonium cation, said phosphate anion, 
said sulfate anion, said acetate anion, and saidpenicillin are in 
a solution having a pH ranging from 3.5 to 10; wherein said 
solution has a temperature ranging from 0° C. to 43° C.; 
wherein each of said potassium cation, said ammonium cat-
ion, said phosphate anion, said sulfate anion, and said acetate 
anion has a molar concentration ranging from 0.01 M to 4.0 M 
and are of a concentration which induces alteration of in situ 
target proteins to establish sensitivity of bacteria to otherwise 
ineffective penicillins. 
2. The pharmaceutical composition of claim 1 wherein said 
potassium cation has a molar concentration of 2.6 M. 
3. The pharmaceutical composition of claim 1 wherein said 
ammonium cation has a molar concentration of 3.7 M. 
4. The pharmaceutical composition of claim 1 wherein said 
phosphate anion has a molar concentration of 3.1 M. 
5. The pharmaceutical composition of claim 1 wherein said 
sulfate anion has a molar concentration of 0.4 M. 
6. The pharmaceutical composition of claim 1 wherein said 
acetate anion has a molar concentration of 0.2 M. 
7. The pharmaceutical composition of claim 1 which fur-
ther includes free ammonia. 
8. The pharmaceutical composition of claim 1 wherein said 
solution is at 22° C. 
9. The pharmaceutical composition of claim 1 wherein said 
solution is at 37° C. 
10. The pharmaceutical composition solution of claim 1 
wherein said bacteria are Gram-positive. 
11. The pharmaceutical composition solution of claim 1 
wherein said bacteria are methicillin-resistant Staphylococ-
cus aureus (MRSA). 
12. The pharmaceutical composition solution of claim 1 
wherein said bacteria are Gram-negative. 
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13. The pharmaceutical composition solution of claim 1 
wherein said bacteria are Pseudomonas aeruginosa. 
14. The pharmaceutical composition solution of claim 1 
wherein said penicillin is semi-synthetic penicillin. 
5 	 15. The pharmaceutical composition solution of claim 1 
wherein said penicillin is cloxacillin. 
16. The pharmaceutical composition solution of claim 1 
wherein said penicillin concentration is between 512 µg/mL 
and 4096 µg/mL. 
io 	 17. A method of making a pharmaceutical composition 
comprising the steps of: 
providing a potassium cation, an ammonium cation, a 
phosphate anion, a sulfate anion, an acetate anion, a 
penicillin; and ammonium hydroxide; placing said 
potassium cation, said ammonium cation, said phos-
phate anion, said sulfate anion, said acetate anion into an 
aqueous solution in a proportional concentration which 
induces alteration of in situ target proteins to establish 
sensitivity of bacteria to otherwise ineffective penicil-
lins; adding said penicillin to said solution; and using 
20 	
said ammonium hydroxide to bring said solution to a 
desired pH. 
18. The method of claim 17 which further comprises the 
step of bringing said solution to a desired temperature. 
19. The method of claim 18 wherein said desired tempera-
25 ture is 22° C. 
20. The method of claim 18 wherein the desired tempera-
ture is 37° C. 
21. The method of claim 17 wherein said composition is 
30 
adapted for administration by topical application. 
22. The method of claim 17 wherein said composition is 
adapted for administration by oral ingestion. 
23. The method of claim 17 wherein said composition is 
adapted for administration by inhalation. 
35 	 24. The method of claim 17 wherein said composition is 
adapted for administration by instillation. 
25. The method of claim 17 wherein said bacteria are in a 
stationary growth phase. 
26. The method of claim 17 wherein said bacteria are in a 
40 
logarithmic growth phase. 
27. The method of claim 17 wherein said bacteria are 
methicillin-resistant Staphylococcus aureus (MRSA). 
28. The method of claim 17 wherein said bacteria are 
Pseudomonas aeruginosa. 
29. The method of claim 17 wherein said penicillin is 
45 
semi-synthetic penicillin. 
30. The method of claim 29 wherein the penicillin is clox-
acillin. 
31. The method of claim 17 wherein said penicillin con-
50 
centration is between 512 µg/ml and 4096 µg/ml. 
32. The method of claim 17 wherein said potassium cation 
has a molar concentration of 2.6 M. 
33. The method of claim 17 wherein said ammonium cat-
ion has a molar concentration of 3.7 M. 
34. The method of claim 17 wherein said phosphate anion 
55 has a molar concentration of 3.1 M. 
35. The method of claim 17 wherein said sulfate anion has 
• molar concentration of 0.4 M. 
36. The method of claim 17 wherein said acetate anion has 
• molar concentration of 0.2 M. 
60 
